Noxafil Schering-Plough Corporation - Treatment for Prevention of Invasive Fungal Infections

Noxafil is a triazole antifungal agent indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age and older who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.

Posted: September 2006

Related Articles:

Noxafil (posaconazole) FDA Approval History

View comments

Hide
(web5)